You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CHOP-R

Showing 1 - 25 of 3,291
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Orelabrutinib + R-CHOP
  • Placebo + R-CHOP
  • Shanghai, Shanghai, China
    Shanghai Ruijing Hospital
Nov 28, 2022

Richter Syndrome Trial in United States (Venetoclax, DA-EPOCH-R, R-CHOP)

Recruiting
  • Richter Syndrome
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Mantle Cell Lymphoma Trial in Beijing

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Hongmei Third Jing
    Jun 20, 2022

    The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)

    Recruiting
    • The First Affiliated Hospital of Nanchang University
    • Nanchang, Jiangxi, China
    • +1 more
    Jul 3, 2023

    Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

    Recruiting
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Westbury, New York
      Clinical Research Alliance Inc
    Oct 13, 2023

    Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

    Active, not recruiting
    • Lymphomas Non-Hodgkin's B-Cell
    • Ballarat, Victoria, Australia
    • +2 more
    Jan 30, 2023

    Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • Shenyang, Liaoning, China
      Xing Xiaojing
    Jun 1, 2023

    Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (Durvalumab, Rituximab, Doxorubicin)

    Completed
    Has Results
    • Lymphoma, Large B-Cell, Diffuse
    • Gilbert, Arizona
    • +18 more
    Aug 19, 2022

    Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Homburg (R-miniCHOP + Acalabrutinib, R-miniCHOP)

    Not yet recruiting
    • Large B-cell Lymphoma
    • Diffuse Large B Cell Lymphoma
    • Homburg, Saarland, Germany
      Saarland University Medical Center
    Apr 19, 2023

    Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

    Withdrawn
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • (no location specified)
    Jun 28, 2023

    Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

    Active, not recruiting
    • Diffuse Large B-cell Lymphoma
    • Shanghai, Shanghai, China
      Shanghai Ruijin Hospital
    Dec 1, 2022

    Follicular Lymphoma (FL) Trial (biological, drug, other)

    Not yet recruiting
    • Follicular Lymphoma (FL)
    • Tisagenlecleucel
    • +4 more
    • (no location specified)
    May 24, 2023

    EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

    Recruiting
    • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
    • Guangzhou, Guangdong, China
    • +1 more
    Nov 10, 2022

    DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Aug 10, 2022

    Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Dec 12, 2022

    Mantle Cell Lymphoma Trial in Guangzhou (R-CHOP/R-DHAOx; Zanubrutib(induction); ASCT conditioning ; Zanubrutinib(Maintenance))

    Recruiting
    • Mantle Cell Lymphoma
    • R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）
    • Guangzhou, Guangdong, China
      Department of Medical Oncology, Sun Yat-sen University Cancer Ce
    Aug 24, 2021

    Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    Apr 24, 2022

    Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • R-CHOP + acalabrutinib
    • Southampton, Hampshire, United Kingdom
    • +6 more
    Oct 26, 2022

    Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Wenzhou, Zhejiang, China
      First Affiliated Hospital of Wenzhou Medical University
    Jun 20, 2022

    Mantle Cell Lymphoma Trial in Canada (Acalabrutinib, R-CHOP chemo)

    Recruiting
    • Mantle Cell Lymphoma
    • Vancouver, British Columbia, Canada
    • +3 more
    Mar 17, 2022

    Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)

    Recruiting
    • Diffuse Large B-cell Lymphoma(DLBCL)
    • Zanubrutinib + R-CHOP
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 10, 2022

    Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib plus RCHOP
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Aug 16, 2023

    Diffuse Large B Cell Lymphoma Trial in Busan (PrednisoLONE 50 MG)

    Completed
    • Diffuse Large B Cell Lymphoma
    • PrednisoLONE 50 MG
    • Busan, Sue-gu, Korea, Republic of
      Kosin University Gospel Hospital
    Mar 31, 2022

    Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +5 more
    • Toripalimab, Rituximab
    • R-CHOP Protocol
    • Guangzhou, Guangdong, China
      Department of hematology department, Nanfang hospital
    Apr 6, 2022

    Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

    Not yet recruiting
    • Primary Extranodal Lymphoma
    • DLBCL
    • (no location specified)
    Apr 6, 2022